NANOPARTICLE FORMULATIONS AND USES THEREOF

• US 20170172975A1
• Filed: 11/29/2016
• Published: 06/22/2017
• Est. Priority Date: 04/10/2009
• Status: Abandoned Application

• Current Assignee: Abraxis Bioscience LLC (Bristol-Myers Squibb Company)
• Original Assignee: Abraxis Bioscience LLC (Bristol-Myers Squibb Company)
• Inventors: CI, Sherry Xiaopei, DE, Tapas, TAO, Chunlin, DESAI, Neil P., TRIEU, Vuong
• Application Number:
  US15/364,189
• Publication Number:
  US 20170172975A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/14 Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51
• CPC Class Codes: A61K 9/146 with organic macromolecular compounds
• CPC Class Codes: A61K 9/5169 Proteins, e.g. albumin, gelatin
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention provides compositions comprising nanoparticles comprising: 1) a drug, such as a hydrophobic drug derivative; and 2) a carrier protein. Also provided are methods of treating diseases (such as cancer) using the compositions, as well as kits and unit dosages.

Claims

1-77. -77. (canceled)

78. :

A method of treating a proliferative disease in an individual, comprising administering to the individual in 10 minutes or less an effective amount of a composition comprising a drug and a carrier protein.

79. :

The method of claim 78, wherein the composition is administered in less than 10 minutes.

80. :

The method of claim 78, wherein the composition is administered in less than 5 minutes.

81. :

The method of claim 78, wherein the composition is administered at a drug dosage of about 5 to about 300 mg/m².

82. :

The method of claim 81, wherein the composition is administered at a drug dosage of about 100 to about 150 mg/m².

83. :

The method of claim 78, wherein the drug is a taxane.

84. :

The method of claim 83, wherein the taxane is paclitaxel.

85. :

The method of claim 78, wherein the proliferative diseases is cancer.

86. :

The method of claim 85, wherein the cancer is a solid tumor.

87. :

The method of claim 85, wherein the cancer is selected from the group consisting of multiple myeloma, renal cell carcinoma, prostate cancer, lung cancer, melanoma, colon cancer, ovarian cancer, and breast cancer.

88. :

The method of claim 87, wherein the cancer is breast cancer.

89. :

The method of claim 78, wherein the composition is administered parenterally.

90. :

The method of claim 89, wherein the composition is administered intravenously.

91. :

The method of claim 78, wherein the composition comprises nanoparticles comprising the drug and the carrier protein.

92. :

The method of claim 91, wherein the carrier protein is albumin.

93. :

The method of claim 91, wherein the nanoparticles comprise the drug coated with the carrier protein.

94. :

The method of claim 93, wherein the carrier protein is albumin.

95. :

The method of claim 91, wherein the nanoparticles have an average particle size of no greater than about 200 nm.

96. :

The method of claim 94, wherein the nanoparticles have an average particle size of no greater than about 200 nm.

97. :

The method of claim 78, wherein the individual is human.